Related Experiment Video
Updated: Feb 10, 2026
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Progression of Liver Fibrosis and Liver-related Event Risk in Metabolic Dysfunction-associated Steatotic Liver
Xiao-Dong Zhou1, Qin-Fen Chen2, Seung Up Kim3
1MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Background & Aims:
Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and high cardiovascular risk often have advanced liver fibrosis, but data on associations and outcomes are limited. The aim of this study was to evaluate the relationships between cardiovascular risk categories and liver fibrosis severity, liver fibrosis progression, and liver-related events (LREs) in MASLD.
Methods:
Patients with MASLD from the VCTE-Prognosis cohort were stratified into low, intermediate, and high cardiovascular risk categories using the Framingham Risk Score (FRS), Primary Care Equivalents (PCE), or Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) scores. Outcomes included the prevalence of advanced fibrosis (liver stiffness ≥10 kPa), liver stiffness progression (≥20% increase and Baveno category upshift), and LRE (hepatocellular carcinoma, hepatic decompensation, liver transplantation, or liver-related mortality). Associations were assessed using multivariable logistic regression and Fine-Gray competing-risks models.
Results:
Among 9312 patients with MASLD (mean age, 54.4 ± 11.0 years; 56.8% male; 87.4% Asian), advanced fibrosis prevalence increased with cardiovascular risk: adjusted odds ratios (ORs) were 2.72 (95% confidence interval [CI], 2.25-3.28; P < .001) for FRS, 1.83 (95% CI, 1.46-2.29; P < .001) for PCE, and 2.93 (95% CI, 2.33-3.69; P < .001) for PREVENT. Over a median follow-up of 4.5 years, liver stiffness progression occurred in 5.0% of patients, more frequently in high-risk groups (adjusted subdistribution hazard ratio [SHR], 1.56; 95% CI, 1.14-2.15; P = .006 for PCE and adjusted SHR, 1.85; 95% CI, 1.33-2.56; P < .001 for PREVENT). LREs occurred in 1.4% of patients, with higher incidence in high-risk groups (adjusted SHR, 2.12; 95% CI, 1.19-3.77; P = .010 for FRS; adjusted SHR, 2.01; 95% CI, 1.08-3.74; P = .027 for PCE; and adjusted SHR, 2.80; 95% CI, 1.40-5.61; P = .004 for PREVENT).
Conclusions:
Higher cardiovascular risk is associated with greater prevalence of advanced liver fibrosis, liver stiffness progression, and LRE incidence in MASLD.
More Related Videos
Related Concept Videos
01:12Relative Risk
01:26Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
01:27Liver Histology
Hepatocytes perform a variety of essential functions. They secrete...
01:30Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
01:24Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
01:17Gross Anatomy of the Liver
Located under the diaphragm, the liver is almost entirely ensconced within the rib cage, providing it with substantial protection. Except for the superior most bare area, the liver's surface is...